- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02245009
Safety of External Electrocardioversion in Device Patients (SEED)
Safety of External Electrocardioversion in Device Patients - the SEED Registry
Arrhythmias of the atria of the heart are a common comorbidity in patients with cardiac rhythm management devices, such as pacemakers and implantable cardioverter/defibrillators (ICD). External electrical cardioversion is an established method to achieve rhythm control (restore normal sinus rhythm) in patients with atrial arrhythmia. Little data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Introduction Atrial arrhythmias are a common comorbidity in patients with cardiac rhythm management (CRM) devices, such as pacemakers and ICD. External electrical cardioversion is an established method to achieve rhythm control in patients with atrial arrhythmia. A paucity of data on safety and efficacy of external electrical cardioversion in patients with cardiac rhythm management devices exists. Most publications are of older date and predominantly case reports or case collections. Few prospective studies with a population of cardiac rhythm management patients after external electrical cardioversion have been published in recent years.
Thus, available data on the safety of external electrical cardioversion in cardiac rhythm management patients lacks statistical power to accurately reflect the true hazard of external electrical cardioversion in patients with cardiac rhythm management devices.
Rationale Electrocardioversion in Propofol sedation for atrial or ventricular tachyarrhythmia is an established therapy. It is routinely used for patients with cardiac rhythm management devices and the risk of device and lead affectation is deemed to be low. This assumption is currently not supported by substantial and current scientific data, mostly relying on older reports. No large, prospective trials with a population of patients with modern cardiac rhythm management devices exists.
Aim of the study The aim is to systematically include and follow all patients with cardiac rhythm management devices presenting for external electrical cardioversion, to analyse the effects of external electrical cardioversion on leads and devices. Thereby, providing reliable evidence and detecting possible SAE with a low incidence. Furthermore, to gather information on efficacy and recurrence rate in this population, to examine the value of external electrical cardioversion for rhythm control in these patients.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
-
Cologne, Allemagne, 50937
- Recrutement
- University Hospital Cologne
-
Contact:
- Daniel Steven, Prof. Dr.
- Numéro de téléphone: 32396 +49221478
- E-mail: daniel.steven@uk-koeln.de
-
Chercheur principal:
- Jakob Lüker, Dr.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥ 18 years
- Informed, written consent
- Atrial or ventricular arrhythmia with indication for CV
- Status post CRM implantation, including CRT-D
Exclusion Criteria:
- Age < 18 years
- Patients under guardianship or with mental disorders / disabilities
- lead implantation < 4 weeks prior to CV
- contraindications for eCV or transoesophageal echocardiographie (TOE)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Pacemaker patients
Patients with pacemaker, presenting for cardioversion.
|
|
ICD patients
Patients with ICD, presenting for cardioversion.
|
|
CRT patients
Patients with CRT device, presenting for cardioversion.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Composite safety endpoint: Changes of lead and device parameters
Délai: 2 weeks after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
2 weeks after CV
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Efficacy Endpoint
Délai: within 15 minutes after CV
|
Assessed by device interrogation and 12-lead ECG: - restoration of normal sinus rhythm after CV |
within 15 minutes after CV
|
Late changes of lead parameters
Délai: 2 weeks after CV
|
Any of the below, assessed by device interrogation:
|
2 weeks after CV
|
Inadvertent induction of ventricular fibrillation
Délai: 10 seconds after CV
|
Assessed by 3 lead monitoring ECG
|
10 seconds after CV
|
Composite endpoint: Early lead changes
Délai: within 15 minutes after CV
|
assessed by device interrogation, if any of the following criteria is met:
|
within 15 minutes after CV
|
Loss of programming
Délai: within 15 minutes after CV
|
assessed by device interrogation: - loss of programming of the device |
within 15 minutes after CV
|
Change of shock impedance
Délai: within 15 minutes after CV
|
assessed by device interrogation: - rise in shock impedance by 50% |
within 15 minutes after CV
|
Change of charge time
Délai: within 15 minutes after CV
|
assessed by device interrogation: - rise in charge time by 50% |
within 15 minutes after CV
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jakob Lüker, Dr., University Hospital Cologne
- Directeur d'études: Daniel Steven, Prof. Dr., University Hospital Cologne
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- UKK-SEED-2014
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cardioversion
-
Tampere UniversityRecrutementFibrillation auriculaire | Flutter auriculaireFinlande
-
University of KentuckyComplétéFibrillation auriculaireÉtats-Unis
-
Hadassah Medical OrganizationInconnueInsuffisance rénale | Fibrillation auriculaire | CardioversionIsraël
-
Medical University of LublinInconnueFibrillation auriculairePologne
-
Mayo ClinicNational Institute on Aging (NIA); Koronis Biomedical TechnologiesRetiréFibrillation auriculaire
-
Bursa Postgraduate HospitalComplétéFibrillation auriculaire
-
Creighton UniversityComplétéFibrillation auriculaireÉtats-Unis
-
Randers Regional HospitalAarhus University HospitalRésiliéFibrillation auriculaire | Flutter auriculaireDanemark
-
Deutsches Herzzentrum MuenchenKlinik für Kardiologie, Klinikum Karlsruhe, Prof. Dr. C. SchmittComplétéFibrillation auriculaire | Flutter auriculaire | AblationAllemagne
-
Uppsala University HospitalSwedish Heart Lung Foundation; Advanz PharmaComplété